A pharmacist dispenses life-saving HIV treatment to a client. The text reads, “In 2005, life-saving HIV treatment cost $1,000 per patient per year, but today, through USAID’s supply chain work, life-saving HIV treatment costs $50 per patient per year.”
Two USAID-supported scientists work together in a lab. The text reads, “For 20 years USAID has been a leader in the development of new HIV prevention tools. Today, USAID is the fourth largest donor of HIV vaccine research and development.”
A provider performs HIV testing. The text reads, “USAID is a proud implementer of PEPFAR, which over the last two decades has saved 25 million lives

As the world's premier international development agency, USAID drives progress through and beyond our programs to confront the greatest challenges of our time, embrace new partnerships, and invest in enduring effectiveness. For over 20 years, USAID has played a critical role in the global HIV/AIDS response, and since 2003 has helped lead the implementation of the President’s Emergency Plan for AIDS Relief (PEPFAR), which has helped over 50 countries curb their HIV epidemics.  

In 2003, only 50,000 people in Africa, where the HIV epidemic hit the hardest, received life-saving HIV treatment. Over the past 20 years, the U.S. government, through PEPFAR, has helped not only save and improve millions of lives, but also transform the global HIV/AIDS response. Through USAID’s leadership in market-shaping interventions which have brought better drugs to market, driven down global prices, and strengthened global supply chains, PEPFAR continues to deliver life-saving HIV treatment to more than 20 million people globally.

Currently, USAID provides over seven million people living with HIV with life-saving HIV-treatment. Ninety-five percent of the people on treatment who received a viral load test remain virally suppressed, meaning that they can live longer, healthier lives and the virus can no longer be transmitted.

However, we have more work to do. At a historic time when controlling the HIV epidemic is within reach, we must continue to effectively engage and meet the needs of key and priority populations disproportionately affected by the HIV epidemic including adolescent girls and young women, men who have sex with men, and transgender people.

USAID already invests in engaging and supporting those who most vulnerable to HIV:

  • In 2022, USAID and our partners supported almost two million members of key populations with HIV prevention services and more than 275 thousand members of key populations in 41 countries are receiving life-saving HIV medication through USAID support;
  • In 2022, USAID initiated almost 230 thousand members of key populations on HIV-prevention medication; 
  • Currently, USAID supports over 5.8 million orphans and vulnerable children and their families affected by HIV with critical services, such as household economic strengthening, education support, parenting skills building, and facilitating access to maternal and child healthcare and HIV specific testing, care, and treatment; and, 
  • In 2022, USAID contributed to supporting over 2.3 million adolescent girls and young women aged 10-24 years with combination HIV prevention services. 

Through our dedicated staff around the world, host country governments, the private sector, philanthropic organizations, multilateral institutions, civil society and faith-based organizations, people living with HIV, and with the strength of our programs, we are well positioned to advance human rights, address inequality, and end HIV as a public health threat by 2030.